AT1 receptor antagonism to reduce aortic expansion in Marfan syndrome: lost in translation or in need of different interpretation?
作者信息
Mallat Ziad, Daugherty Alan
机构信息
From the Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge, Cambridge, United Kingdom (Z.M.); and Saha Cardiovascular Research Center, University of Kentucky, Lexington (A.D.)
From the Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge, Cambridge, United Kingdom (Z.M.); and Saha Cardiovascular Research Center, University of Kentucky, Lexington (A.D.).
出版信息
Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):e10-2. doi: 10.1161/ATVBAHA.114.305173. Epub 2014 Dec 30.
Abstract
摘要
相似文献
1
AT1 receptor antagonism to reduce aortic expansion in Marfan syndrome: lost in translation or in need of different interpretation?血管紧张素Ⅱ1型受体拮抗剂对减轻马方综合征主动脉扩张的作用：是翻译有误还是需要不同的解读？
Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):e10-2. doi: 10.1161/ATVBAHA.114.305173. Epub 2014 Dec 30.
2
Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.氯沙坦是一种血管紧张素Ⅱ1型受体（AT1）拮抗剂，可在马方综合征小鼠模型中预防主动脉瘤形成。
Science. 2006 Apr 7;312(5770):117-21. doi: 10.1126/science.1124287.
3
The Effect of a Nonpeptide Angiotensin II Type 2 Receptor Agonist, Compound 21, on Aortic Aneurysm Growth in a Mouse Model of Marfan Syndrome.非肽类血管紧张素II 2型受体激动剂化合物21对马凡综合征小鼠模型主动脉瘤生长的影响
J Cardiovasc Pharmacol. 2018 Apr;71(4):215-222. doi: 10.1097/FJC.0000000000000560.
4
Localized Antileptin Therapy Prevents Aortic Root Dilatation and Preserves Left Ventricular Systolic Function in a Murine Model of Marfan Syndrome.局部抗瘦素治疗可预防马凡综合征小鼠模型的主动脉根部扩张并维持左心室收缩功能。
J Am Heart Assoc. 2020 May 18;9(10):e014761. doi: 10.1161/JAHA.119.014761. Epub 2020 May 7.
5
Medicine. Old drug, new hope for Marfan syndrome.医学。旧药为马凡氏综合征带来新希望。
Science. 2006 Apr 7;312(5770):36-7. doi: 10.1126/science.312.5770.36b.
6
Of Marfan's syndrome, mice, and medications.关于马凡氏综合征、小鼠与药物。
N Engl J Med. 2014 Nov 27;371(22):2127-8. doi: 10.1056/NEJMe1412950. Epub 2014 Nov 18.
7
Atenolol versus Losartan in Marfan's Syndrome.阿替洛尔与氯沙坦治疗马方综合征的比较。
N Engl J Med. 2015 Mar 5;372(10):980. doi: 10.1056/NEJMc1500128.
8
Atenolol versus Losartan in Marfan's Syndrome.阿替洛尔与氯沙坦治疗马方综合征的比较。
N Engl J Med. 2015 Mar 5;372(10):978-9. doi: 10.1056/NEJMc1500128.
9
Atenolol versus Losartan in Marfan's Syndrome.阿替洛尔与氯沙坦治疗马方综合征的对比研究
N Engl J Med. 2015 Mar 5;372(10):977-8. doi: 10.1056/NEJMc1500128.
10
Atenolol versus Losartan in Marfan's Syndrome.阿替洛尔与氯沙坦治疗马方综合征的对比研究
N Engl J Med. 2015 Mar 5;372(10):980-1. doi: 10.1056/NEJMc1500128.
引用本文的文献
1
Molecular Mechanisms in Genetic Aortopathy-Signaling Pathways and Potential Interventions.遗传性主动脉病的分子机制-信号通路与潜在干预措施。
Int J Mol Sci. 2023 Jan 16;24(2):1795. doi: 10.3390/ijms24021795.
2
Pharmacologic Management of Aneurysms.动脉瘤的药物治疗管理。
Circ Res. 2019 Feb 15;124(4):631-646. doi: 10.1161/CIRCRESAHA.118.312439.
3
Therapies for Thoracic Aortic Aneurysms and Acute Aortic Dissections.胸主动脉瘤和急性主动脉夹层的治疗方法。
Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):126-136. doi: 10.1161/ATVBAHA.118.310956.
4
Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.血管紧张素 II 信号转导：对生理和病理生理学机制的最新研究。
Physiol Rev. 2018 Jul 1;98(3):1627-1738. doi: 10.1152/physrev.00038.2017.
5
Role of the LDL Receptor-Related Protein 1 in Regulating Protease Activity and Signaling Pathways in the Vasculature.载脂蛋白 E 受体相关蛋白 1 在调节血管中蛋白酶活性和信号通路中的作用。
Curr Drug Targets. 2018;19(11):1276-1288. doi: 10.2174/1389450119666180511162048.
6
TGF-β Family Signaling in Connective Tissue and Skeletal Diseases.TGF-β 家族信号在结缔组织和骨骼疾病中的作用。
Cold Spring Harb Perspect Biol. 2017 Nov 1;9(11):a022269. doi: 10.1101/cshperspect.a022269.
本文引用的文献
1
Atenolol versus losartan in children and young adults with Marfan's syndrome.阿替洛尔与氯沙坦用于患有马凡氏综合征的儿童和年轻人的比较。
N Engl J Med. 2014 Nov 27;371(22):2061-71. doi: 10.1056/NEJMoa1404731. Epub 2014 Nov 18.
2
Angiotensin II induces region-specific medial disruption during evolution of ascending aortic aneurysms.在升主动脉瘤的发展过程中，血管紧张素II会引发特定区域的中膜破坏。
Am J Pathol. 2014 Sep;184(9):2586-95. doi: 10.1016/j.ajpath.2014.05.014. Epub 2014 Jul 16.
3
Tgfbr2 disruption in postnatal smooth muscle impairs aortic wall homeostasis.Tgfbr2 缺失导致出生后平滑肌功能障碍，破坏主动脉壁内稳态。
J Clin Invest. 2014 Feb;124(2):755-67. doi: 10.1172/JCI69942. Epub 2014 Jan 9.
4
5
Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial.氯沙坦可降低马凡综合征成年患者的主动脉扩张速度：一项随机对照试验。
Eur Heart J. 2013 Dec;34(45):3491-500. doi: 10.1093/eurheartj/eht334. Epub 2013 Sep 2.
6
Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study.氯沙坦联合β受体阻滞剂治疗马凡综合征升主动脉扩张的随机、开放标签初步研究。
Mayo Clin Proc. 2013 Mar;88(3):271-6. doi: 10.1016/j.mayocp.2012.11.005. Epub 2013 Jan 12.
7
In vivo characterization of a new abdominal aortic aneurysm mouse model with conventional and molecular magnetic resonance imaging.应用常规和分子磁共振成像对新型腹主动脉瘤小鼠模型进行体内特征分析。
J Am Coll Cardiol. 2011 Dec 6;58(24):2522-30. doi: 10.1016/j.jacc.2011.09.017.
8
Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis.不同模式肾素-血管紧张素系统抑制对高胆固醇血症诱导动脉粥样硬化的比较作用。
Br J Pharmacol. 2012 Mar;165(6):2000-2008. doi: 10.1111/j.1476-5381.2011.01712.x.
9
Lessons on the pathogenesis of aneurysm from heritable conditions.遗传性疾病对动脉瘤发病机制的启示。
Nature. 2011 May 19;473(7347):308-16. doi: 10.1038/nature10145.
10
The role of the renin-angiotensin system in thoracic aortic aneurysms: clinical implications.肾素-血管紧张素系统在胸主动脉瘤中的作用：临床意义。
Pharmacol Ther. 2011 Jul;131(1):50-60. doi: 10.1016/j.pharmthera.2011.04.002. Epub 2011 Apr 12.
Zotero 插件